Increasing Antimicrobial Resistance in Nontyphoidal Salmonella Isolates in Australia from 1979 to 2015

Antimicrob Agents Chemother. 2018 Jan 25;62(2):e02012-17. doi: 10.1128/AAC.02012-17. Print 2018 Feb.

Abstract

Australia has high and increasing rates of salmonellosis. To date, the serovar distribution and associated antimicrobial resistance (AMR) patterns of nontyphoidal Salmonella enterica (NTS) in Australia have not been assessed. Such information provides critical knowledge about AMR in the food chain and informs decisions about public health. We reviewed longitudinal data on NTS in two Australian states over a 37-year period, between 1979 and 2015, and antimicrobial resistance since 1984. Overall, 17% of isolates were nonsusceptible to at least one antimicrobial, 4.9% were nonsusceptible to ciprofloxacin, and 0.6% were nonsusceptible to cefotaxime. In total, 2.5% of isolates were from invasive infections, with no significant difference in AMR profiles between invasive and noninvasive isolates. Most isolates with clinically relevant AMR profiles were associated with travel, particularly to Southeast Asia, with multiple "incursions" of virulent and resistant clones into Australia. Our findings represent the largest longitudinal surveillance system for NTS in Australia and provide valuable public health knowledge on the trends and distribution of AMR in NTS. Ongoing surveillance is critical to identify local emergence of resistant isolates.

Keywords: Salmonella; Salmonella enterica; antimicrobial resistance; epidemiology; public health; surveillance studies; zoonotic infections.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Australia / epidemiology
  • Cefotaxime / therapeutic use
  • Ciprofloxacin / therapeutic use
  • Drug Resistance, Bacterial / drug effects*
  • Humans
  • Microbial Sensitivity Tests / methods
  • Salmonella Infections / drug therapy*
  • Salmonella Infections / epidemiology*
  • Salmonella enterica / drug effects*
  • Serogroup

Substances

  • Anti-Bacterial Agents
  • Ciprofloxacin
  • Cefotaxime